The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants
Status:
Completed
Trial end date:
1994-06-01
Target enrollment:
Participant gender:
Summary
To determine whether the rate of HIV transmission from mother to infant can be reduced by
continuous oral zidovudine (AZT) treatment to HIV infected pregnant women, intravenous AZT
during childbirth, and oral AZT treatment of the newborn infant from birth to six weeks of
age. The study is also designed to evaluate the safety of AZT for both the pregnant woman and
the newborn infant.
No method exists to prevent transmission of HIV from an infected mother to her newborn
infant. Giving an antiviral agent (such as AZT) to the mother and to the newborn could in
theory decrease the risk of infection to the newborn by reducing the exposure of the fetus to
maternal virus, or by preventive treatment of the fetus before exposure.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)